News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
189,998 Results
Type
Article (15147)
Company Profile (25)
Press Release (174826)
Multimedia
Podcasts (22)
Webinars (5)
Section
Business (53396)
Career Advice (661)
Deals (9756)
Drug Delivery (38)
Drug Development (29994)
Employer Resources (74)
FDA (4961)
Job Trends (4205)
News (98447)
Policy (8414)
Tag
Academia (1109)
Academic (1)
Accelerated approval (1)
Adcomms (7)
Allergies (36)
Alliances (14895)
ALS (37)
Alzheimer's disease (482)
Antibody-drug conjugate (ADC) (33)
Approvals (4966)
Artificial intelligence (70)
Autoimmune disease (9)
Automation (4)
Bankruptcy (71)
Best Places to Work (3399)
BIOSECURE Act (6)
Biosimilars (39)
Biotechnology (11)
Bladder cancer (25)
Brain cancer (9)
Breast cancer (94)
Cancer (673)
Cardiovascular disease (67)
Career advice (559)
Career pathing (15)
CAR-T (47)
Cell therapy (120)
Cervical cancer (11)
Clinical research (25327)
Collaboration (206)
Compensation (19)
Complete response letters (3)
COVID-19 (1178)
CRISPR (8)
C-suite (70)
Cystic fibrosis (20)
Data (773)
Denatured (7)
Depression (11)
Diabetes (102)
Diagnostics (1839)
Digital health (3)
Diversity (5)
Diversity, equity & inclusion (28)
Drug discovery (43)
Drug pricing (40)
Drug shortages (18)
Duchenne muscular dystrophy (40)
Earnings (15555)
Editorial (20)
Employer branding (8)
Employer resources (67)
Events (22083)
Executive appointments (220)
FDA (5312)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (216)
Gene editing (20)
Generative AI (6)
Gene therapy (99)
GLP-1 (308)
Government (1298)
Grass and pollen (2)
Guidances (12)
Healthcare (5694)
Huntington's disease (9)
IgA nephropathy (10)
Immunology and inflammation (42)
Indications (7)
Infectious disease (1224)
Inflammatory bowel disease (58)
Inflation Reduction Act (4)
Influenza (17)
Intellectual property (19)
Interviews (109)
IPO (3624)
IRA (20)
Job creations (936)
Job search strategy (490)
Kidney cancer (2)
Labor market (8)
Layoffs (119)
Leadership (10)
Legal (1678)
Liver cancer (28)
Lung cancer (83)
Lymphoma (45)
Machine learning (2)
Management (23)
Manufacturing (84)
MASH (33)
Medical device (3277)
Medtech (3279)
Mergers & acquisitions (6277)
Metabolic disorders (253)
Multiple sclerosis (48)
NASH (16)
Neurodegenerative disease (31)
Neuropsychiatric disorders (6)
Neuroscience (692)
NextGen: Class of 2025 (2113)
Non-profit (1712)
Now hiring (1)
Obesity (125)
Opinion (67)
Ovarian cancer (19)
Pain (32)
Pancreatic cancer (22)
Parkinson's disease (57)
Partnered (7)
Patents (36)
Patient recruitment (38)
Peanut (18)
People (19368)
Pharmaceutical (11)
Pharmacy benefit managers (9)
Phase I (5789)
Phase II (10880)
Phase III (10247)
Pipeline (323)
Policy (62)
Postmarket research (1268)
Preclinical (2118)
Press Release (29)
Prostate cancer (39)
Psychedelics (10)
Radiopharmaceuticals (68)
Rare diseases (115)
Real estate (1504)
Recruiting (26)
Regulatory (6135)
Reports (16)
Research institute (946)
Resumes & cover letters (88)
Rett syndrome (1)
RNA editing (1)
RSV (19)
Schizophrenia (28)
Series A (52)
Series B (35)
Service/supplier (2)
Sickle cell disease (13)
Special edition (4)
Spinal muscular atrophy (84)
Sponsored (5)
Startups (1281)
Stomach cancer (5)
Supply chain (17)
Tariffs (18)
The Weekly (15)
Vaccines (294)
Venture capitalists (11)
Weight loss (90)
Women's health (15)
Worklife (7)
Date
Today (39)
Last 7 days (195)
Last 30 days (626)
Last 365 days (8525)
2025 (2724)
2024 (9065)
2023 (10290)
2022 (14612)
2021 (15882)
2020 (15285)
2019 (14279)
2018 (11077)
2017 (10050)
2016 (9706)
2015 (11555)
2014 (7956)
2013 (6281)
2012 (6808)
2011 (7256)
2010 (6348)
Location
Africa (287)
Alabama (7)
Alaska (4)
Arizona (47)
Arkansas (2)
Asia (13088)
Australia (2480)
California (1333)
Canada (393)
China (162)
Colorado (51)
Connecticut (54)
Delaware (37)
Europe (35688)
Florida (176)
Georgia (73)
Idaho (14)
Illinois (154)
India (10)
Indiana (91)
Iowa (2)
Japan (71)
Kansas (30)
Kentucky (7)
Louisiana (6)
Maine (11)
Maryland (224)
Massachusetts (888)
Michigan (42)
Minnesota (97)
Missouri (18)
Montana (6)
Nebraska (6)
Nevada (19)
New Hampshire (10)
New Jersey (464)
New Mexico (7)
New York (539)
North Carolina (180)
Northern California (574)
Ohio (39)
Oklahoma (3)
Oregon (4)
Pennsylvania (310)
Puerto Rico (3)
Rhode Island (6)
South America (409)
South Carolina (8)
Southern California (537)
Tennessee (18)
Texas (159)
United States (5209)
Utah (28)
Virginia (30)
Washington D.C. (9)
Washington State (168)
Wisconsin (12)
189,998 Results for "roche group".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Immunology and inflammation
First Head-to-Head Study Cements Roche’s Xolair as Food Allergy Leader
Roche’s asthma drug Xolair appears to be safer and more effective than oral immunotherapy at treating adults and children with one or more food allergies.
March 3, 2025
·
2 min read
·
Tristan Manalac
Tariffs
Roche in ‘Very, Very Good Position’ To Weather Trump Tariffs but M&A May Suffer
Roche’s exposure to the tariffs is mostly limited to four medicines, three of which it already produces in the U.S., according to CEO Thomas Schinecker, who declined to reveal what these assets are.
April 24, 2025
·
2 min read
·
Tristan Manalac
Antibody-drug conjugate (ADC)
Roche Ups ADC Bet With $1B in Biobucks for Oxford BioTherapeutics
Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for undisclosed cancer targets.
March 19, 2025
·
1 min read
·
Tristan Manalac
Gene therapy
Roche Absorbs $2.4B Impairment in Overhaul of Spark Gene Therapy Unit
Roche acquired Spark Therapeutics in 2019 for $4.8 billion.
March 11, 2025
·
2 min read
·
Tristan Manalac
Manufacturing
Roche, Regeneron Pledge Multibillion Boosts to US Manufacturing as Trump’s Tariffs Loom
Roche is committing $50 billion while Regeneron inked a $3 billion manufacturing deal with Fujifilm, allowing the pharma to “nearly double” its U.S. large-scale manufacturing capacity.
April 22, 2025
·
2 min read
·
Tristan Manalac
Earnings
Roche to Stay ‘Disciplined’ With Deals in 2025
For 2025, Roche will continue a careful approach to high-priced deals, putting science at the center of its business development decisions, executives said Thursday.
January 30, 2025
·
2 min read
·
Tristan Manalac
Weight loss
Roche Makes Another Obesity Play With Potential $5.3B Amylin Pact With Zealand
Roche and Zealand plan to study petrelintide as a monotherapy and in combination with CT-388, a dual agonist of the GLP-1 and GIP receptors that Roche picked up in its recent acquisition of Carmot Therapeutics.
March 12, 2025
·
2 min read
·
Tristan Manalac
Earnings
Roche Beats Q3 Sales Estimates as CEO Voices Opposition to Novo Holdings’ Catalent Buyout
Jefferies analyst Peter Welford noted that Roche’s pharma group came just slightly ahead of consensus expectations, driven by strong performance of its multiple sclerosis therapy Ocrevus and eye injection Vabysmo.
October 23, 2024
·
3 min read
·
Tristan Manalac
Press Releases
CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings
April 30, 2025
·
10 min read
Neuropsychiatric disorders
Newleos Raises $93.5M to Advance Neuropsychiatric Cast-Offs from Roche
Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.
February 13, 2025
·
3 min read
·
Dan Samorodnitsky
1 of 19,000
Next
